Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty.
This study sought to evaluate the effect of cilostazol in preventing restenosis after successful percutaneous transluminal coronary angioplasty (PTCA) in 68 patients: 35 patients received cilostazol immediately after PTCA and 33 patients received aspirin or ticlopidine. Repeat coronary angiography was performed 4 to 6 months after PTCA and the incidence of restenosis was significantly lower (17%) in the cilostazol group than in the non-cilostazol group (40%) (p < 0.05), which indicates that cilostazol has the potential to prevent restenosis after PTCA.
Take
S
S
Department of Cardiology, Saiseikai Noe Hospital, Osaka City, Japan.
Matsutani
M
M
Ueda
H
H
Hamaguchi
H
H
Konishi
H
H
Baba
Y
Y
Kawaratani
H
H
Sugiura
T
T
Iwasaka
T
T
Inada
M
M
D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000077407:Cilostazol; D003327:Coronary Disease / Q000188:drug therapy* / Q000517:prevention & control* / Q000628:therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012008:Recurrence; D013777:Tetrazoles / Q000627:therapeutic use*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*
D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D014665:Vasodilator Agents; D000077407:Cilostazol